1
|
Loi M, Salvatore G, Sottili M, Calosi L, Desideri I, Becherini C, Salvestrini V, Ciccone LP, Stocchi G, Meattini I, Francolini G, Mangoni M, Livi L. Tumor-associated macrophages (TAMs) modulate response to HER2-targeted agents in a humanized mouse model of breast cancer. Clin Transl Oncol 2022; 24:1395-1402. [PMID: 35212924 DOI: 10.1007/s12094-022-02785-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2021] [Accepted: 01/20/2022] [Indexed: 11/26/2022]
Abstract
PURPOSE Tumor-associated macrophages (TAM) may participate to antitumor activity of anti-HER2-targeted therapies (Pertuzumab, Trastuzumab) in breast cancers harbouring HER-2 overexpression through antibody-dependent phagocytosis. Additive antitumor effect of concurrent cytotoxic chemotherapies, including Paclitaxel, may be counterbalanced by alteration in TAM infiltrate. The aim of this study is to evaluate the role of TAM in tumor response to anti-HER2-targeted therapies and chemotherapy in an experimental model of HER2-amplified breast cancer. METHODS A xenograft mouse model was built by subcutaneous injection of the SKBR-3 human HER2-amplified breast cancer cell line in Hu-CD34+ mice. Animals were randomized to receive weekly administration of Cremophor (control), Trastuzumab+Pertuzumab (TP), and Paclitaxel+Trastuzumab+Pertuzumab (PTP) with or without macrophage depletion with clodronate (C). At week 4, mice were euthanised and tumors were harvested for immunohistochemical analysis of TAM infiltration (RBP-J CD163 and CD68 for M1, M2, and overall TAM, respectively). RESULTS Tumor size was significantly lower in mice treated with TP, PTP, and PTP+C as compared to control, while no meaningful difference was observed in the TP+C arm. Analysis of TAM infiltrate showed significantly lower CD68 and CD163 expression in PTP, TP+C, and PTP+C as compared to TP and control arm. RBP-J expression was significantly decreased in mice treated with clodronate depletion. CONCLUSIONS Activity of TP is modulated by TAM infiltrate, that is inhibited by concurrent administration of Paclitaxel. To enhance the effect of anti-HER2-targeted therapies and minimize chemotherapy-related side effects, modulation of TAM should be considered in novel therapeutic combinations.
Collapse
Affiliation(s)
- M Loi
- Radiotherapy Department, University of Florence, 3, Largo Brambilla, 50124, Florence, Italy.
| | - G Salvatore
- Radiotherapy Department, University of Florence, 3, Largo Brambilla, 50124, Florence, Italy
| | - M Sottili
- Radiotherapy Department, University of Florence, 3, Largo Brambilla, 50124, Florence, Italy
| | - L Calosi
- Department of Experimental and Clinical Medicine, Section of Anatomy and Histology, Research Unit of Histology an Embryology, University of Florence, Florence, Italy
| | - I Desideri
- Radiotherapy Department, University of Florence, 3, Largo Brambilla, 50124, Florence, Italy
- Department of Biomedical and Experimental Sciences, University of Florence, Florence, Italy
| | - C Becherini
- Radiotherapy Department, University of Florence, 3, Largo Brambilla, 50124, Florence, Italy
| | - V Salvestrini
- Radiotherapy Department, University of Florence, 3, Largo Brambilla, 50124, Florence, Italy
| | - L P Ciccone
- Radiotherapy Department, University of Florence, 3, Largo Brambilla, 50124, Florence, Italy
| | - G Stocchi
- Radiotherapy Department, University of Florence, 3, Largo Brambilla, 50124, Florence, Italy
| | - I Meattini
- Radiotherapy Department, University of Florence, 3, Largo Brambilla, 50124, Florence, Italy
- Department of Biomedical and Experimental Sciences, University of Florence, Florence, Italy
| | - G Francolini
- Radiotherapy Department, University of Florence, 3, Largo Brambilla, 50124, Florence, Italy
| | - M Mangoni
- Radiotherapy Department, University of Florence, 3, Largo Brambilla, 50124, Florence, Italy
- Department of Biomedical and Experimental Sciences, University of Florence, Florence, Italy
| | - L Livi
- Radiotherapy Department, University of Florence, 3, Largo Brambilla, 50124, Florence, Italy
- Department of Biomedical and Experimental Sciences, University of Florence, Florence, Italy
| |
Collapse
|
2
|
Bormioli S, Vultaggio A, Nencini F, Comin CE, Bercich L, Bezzi M, Vivarelli E, Calosi L, Chiccoli F, Matucci A. Benralizumab: Resolution of Eosinophilic Pulmonary Vasculitis in a Patient With EGPA. J Investig Allergol Clin Immunol 2021; 31:519-521. [PMID: 34935618 DOI: 10.18176/jiaci.0689] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- S Bormioli
- Immunology and Cellular Therapy, AOU Careggi, University of Florence, Florence, Italy
| | - A Vultaggio
- Immunoallergology Unit, AOU Careggi, University of Florence, Florence, Italy
| | - F Nencini
- Immunoallergology Unit, AOU Careggi, University of Florence, Florence, Italy
| | - C E Comin
- Department of Experimental and Clinical Medicine Section of Surgery, Histopathology and Molecular Pathology, University of Florence, Florence, Italy
| | - L Bercich
- Department of Pathology, ASST Spedali Civili of Brescia, Brescia, Italy
| | - M Bezzi
- UOC Pneumology Endoscopic Unit, ASST Spedali Civili of Brescia, Brescia, Italy
| | - E Vivarelli
- Immunoallergology Unit, AOU Careggi, University of Florence, Florence, Italy
| | - L Calosi
- Department of Experimental & Clinical Medicine, Section of Anatomy & Histology & Research Unit of Histology & Embryology, University of Florence, Florence, Italy
| | - F Chiccoli
- Immunology and Cellular Therapy, AOU Careggi, University of Florence, Florence, Italy
| | - A Matucci
- Immunoallergology Unit, AOU Careggi, University of Florence, Florence, Italy
| |
Collapse
|
3
|
Pini A, Garella R, Idrizaj E, Calosi L, Baccari MC, Vannucchi MG. Glucagon-like peptide 2 counteracts the mucosal damage and the neuropathy induced by chronic treatment with cisplatin in the mouse gastric fundus. Neurogastroenterol Motil 2016; 28:206-16. [PMID: 26547262 DOI: 10.1111/nmo.12712] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/30/2015] [Accepted: 09/28/2015] [Indexed: 12/16/2022]
Abstract
BACKGROUND Glucagon-like peptide-2 (GLP-2) is a pleiotropic hormone synthesized and secreted by the enteroendocrine 'L' cells able to exert intestine-trophic and anti-inflammatory effects. The antineoplastic drug cisplatin causes gastrointestinal alterations with clinical symptoms (nausea and vomiting) that greatly affect the therapy compliance. Experimentally, it has been reported that chronic cisplatin treatment caused mucosal damage and enteric neuropathy in the rat colon. METHODS We investigated, through a combined immunohistochemical and functional approach, whether [Gly(2) ]GLP-2, a GLP-2 analog, was able to counteract the detrimental effects of long-term cisplatin administration in the mucosa and myenteric neurons of mouse gastric fundus. KEY RESULTS Morphological experiments showed a reduction in the epithelium thickness in cisplatin-treated mice, which was prevented by [Gly(2) ]GLP-2 co-treatment. Immunohistochemistry demonstrated that cisplatin caused a significant decrease in myenteric neurons, mainly those expressing neuronal nitric oxide synthase (nNOS), that was prevented by [Gly(2) ]GLP-2 co-treatment. In the functional experiments, [Gly(2) ]GLP-2 co-treatment counteracted the increase in amplitude of the neurally induced contractions observed in strips from cisplatin-treated animals. The NO synthesis inhibitor L-N(G) -nitro arginine caused an increase in amplitude of the contractile responses that was greater in preparations from cisplatin+[Gly(2) ]GLP-2 treated mice compared to the cisplatin-treated ones. CONCLUSIONS & INFERENCES The results demonstrate that in cisplatin long-term treated mice [Gly(2) ]GLP-2 is able to counteract both the mucosal gastric fundus damage, by preventing the epithelium thickness decrease, and the neuropathy, by protecting the nNOS neurons. Taken together, the present data suggest that [Gly(2) ]GLP-2 could represent an effective strategy to overcome the distressing gastrointestinal symptoms present during the anti-neoplastic therapy.
Collapse
Affiliation(s)
- A Pini
- Department of Experimental and Clinical Medicine, Histology and Embryology Research Unit, University of Florence, Florence, Italy
| | - R Garella
- Department of Experimental and Clinical Medicine, Section of Physiological Sciences, University of Florence, Florence, Italy
| | - E Idrizaj
- Department of Experimental and Clinical Medicine, Section of Physiological Sciences, University of Florence, Florence, Italy
| | - L Calosi
- Department of Experimental and Clinical Medicine, Histology and Embryology Research Unit, University of Florence, Florence, Italy
| | - M C Baccari
- Department of Experimental and Clinical Medicine, Section of Physiological Sciences, University of Florence, Florence, Italy
| | - M G Vannucchi
- Department of Experimental and Clinical Medicine, Histology and Embryology Research Unit, University of Florence, Florence, Italy
| |
Collapse
|
5
|
Cavone L, Calosi L, Cinci L, Moroni F, Chiarugi A. Topical mannitol reduces inflammatory edema in a rat model of arthritis. Pharmacology 2012; 89:18-21. [PMID: 22236612 DOI: 10.1159/000335094] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2011] [Accepted: 11/04/2011] [Indexed: 11/19/2022]
Abstract
The hexahydric alcohol mannitol is widely used to shift fluids from the intracellular to the extracellular compartments, to increase diuresis and improve mucus clearance in the airways. In principle, because of its physicochemical properties, topical mannitol might also draw fluids out of epidermis or mucosa. Here, we report that topical mannitol applications on the hind paws of rats with adjuvant-induced arthritis reduced paw thickness and tissue edema without affecting the inflammatory infiltrates. Of note, the anti-edema effects of acute (4 h) mannitol application occurred earlier than those prompted by a similar treatment with classic anti-inflammatory drugs such as diclofenac or ketoprofen. Yet, the extent of edema reduction was higher with diclofenac or ketoprofen than with mannitol when the drugs were applied in a chronic (16 h) paradigm. Together, data demonstrate that topical application of mannitol exerts potent and fast anti-edema effects in a rat model of joint inflammation, suggesting a possible utilization in patients affected by osseo-arthritic disorders.
Collapse
Affiliation(s)
- L Cavone
- Department of Preclinical and Clinical Pharmacology, University of Florence, Florence, Italy.
| | | | | | | | | |
Collapse
|